<DOC>
	<DOCNO>NCT02201407</DOCNO>
	<brief_summary>This open -- label , multicenter , national observational study investigate effectiveness standard care treatment peginterferon alfa-2a participant chronic hepatitis B ( CHB ) . Participants never receive hepatitis B virus ( HBV ) treatment participant previously treat nucleos ( ) ide analog ( NAs ) qualify enrollment . The observation period 48 week ( peginterferon alfa -- 2a standard care treatment ) 24 week thereafter ( 72 week total ) .</brief_summary>
	<brief_title>An Observational Study Participants With Chronic Hepatitis B ( CHB ) Receiving Therapy With Peginterferon Alfa-2a 40 Kilodaltons ( kD ) ( PEGASYS ) - The PRO B Study</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>HBeAg positive HBeAg negative serologically proven CHB without cirrhosis ( histologically verify point past ) Baseline HBV DNA great ( &gt; ) 2000 IU/mL Elevated serum ALT &gt; upper limit normal ( ULN ) Participants treat previous NAs therapy eligible study Participants contraindication peginterferon alfa2a accordance approve summary product characteristic ( example , severe psychiatric disease , immunological disease , severe hepatic dysfunction decompensated cirrhosis liver severe retinopathy thyroid dysfunction , autoimmune hepatitis , history severe preexist cardiac disease , hypersensitivity active substance , alpha interferon , excipients ) Participants ALT &gt; 10 time ULN evidence hepatocellular carcinoma Participants serological evidence coinfection hepatitis A virus , hepatitis C virus , human immunodeficiency virus , hepatitis D virus Participants decompensated liver disease Pregnant breastfeed woman A history liver transplantation plan liver transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>